<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230815059151N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-14</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of low-level laser in reducing obsessive-compulsive symptoms</public_title>
      <acronym></acronym>
      <scientific_title>Therapeutic effects of low-level laser therapy in reducing obsessive compulsive disorder symptoms in bipolar patient treatment Compared with the control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72085</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: The patients and the researcher are blinded in the study and the third party arranges the samples in two groups in such a way that in terms of age and sex, level of education, marital status, duration of the onset of the disease, the amount of previous hospitalization, the type of drug and the equivalent dose, they are almost identical. There is a similar one in another group. This third party will also place the laser device on the patient's head.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Obsessive compulsive disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention group will be formed by patients who receive laser therapy as an adjuvant treatment in the first four weeks of outpatient visits. This group is treated with low-power laser for 9 sessions over a period of 4 weeks. 24 semi-conductor lasers with a power of 100 mW are used for laser treatment of patients, which are placed on a helmet. 12 of the lasers have a visible wavelength of 630 nm and the other 12 have a wavelength of 810 nm. The laser beam is pulsed with a frequency of 75 Hz and a duty cycle of 20 percent for 10 to 20 minutes to the scalp area of the patients. According to the diameter of the laser beam on the skull surface of the patients, which is 0.21 cm2, the power density and energy density applied to the patients in each session are 0.9 W/cm2 and 56.5 J/cm2, respectively. Intervention 2: Control group: The control group is treated with a silent laser device with zero intensity in the first 4 weeks of outpatient visits for 9 sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Main outcome information and aggregate data can be shared after de-identifying individuals.

When:
Immediately after printing the results

To whom:
All researchers working in academic and scientific institutions and people working in the industry and all those interested

Conditions:
By observing the ethical principles, it is possible to use the data for future research or other purposes.

Where to obtain:
By phone or e-mail address (Ali_md07@yahoo.com) with the person responsible for the study

How to obtain:
Providing explanations for where and how to use data by explaining ethical protocols

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Faghfouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 4, No 85, Hayamanesh st, Dabestan, seyyed khandan, Tehran, iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1631668115</zip>
        <telephone>+98 21 8846 9459</telephone>
        <email>ali_md07@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Faghfouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 4, No 85, Hayamanesh st, Dabestan, seyyed khandan, Tehran, iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1631668115</zip>
        <telephone>+98 21 8846 9459</telephone>
        <email>ali_md07@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing OCD treatment are referred to a psychiatric clinic as outpatients
Age above 18 years
No claustrophobia
Patients should be in drug stabilization for at least 2 months
The patient is not psychotic</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with a history of neurological disease such as epilepsy
Having other neurological disorders such as parkinsonism
Traumatic brain injury
Brain stroke
pregnancy
Acute and chronic physical illness
Cases receiving antidepressant treatment or ECT (convulsive therapy with electroshock).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F42</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Obsessive-compulsive disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group will be formed by patients who receive laser therapy as an adjuvant treatment in the first four weeks of outpatient visits. This group is treated with low-power laser for 9 sessions over a period of 4 weeks. 24 semi-conductor lasers with a power of 100 mW are used for laser treatment of patients, which are placed on a helmet. 12 of the lasers have a visible wavelength of 630 nm and the other 12 have a wavelength of 810 nm. The laser beam is pulsed with a frequency of 75 Hz and a duty cycle of 20 percent for 10 to 20 minutes to the scalp area of the patients. According to the diameter of the laser beam on the skull surface of the patients, which is 0.21 cm2, the power density and energy density applied to the patients in each session are 0.9 W/cm2 and 56.5 J/cm2, respectively.</i_keyword>
      <i_keyword>Control group: The control group is treated with a silent laser device with zero intensity in the first 4 weeks of outpatient visits for 9 sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>OCD severity based on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Timepoint: Measuring the level of obsessive compulsive disorder before the start of treatment and then at the end of treatment and one month after the last treatment in an outpatient visit to a psychiatric clinic. Method of measurement: Yale-Brown Obsessive Compulsive Scale Questionnaire (Y-BOCS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-27</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>6th floor,Building No. 2,Shahid Beheshti University of Medical Science,Shahid Arabi,Yemen St,Shahid Chamran Highway,Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
